Clinical Trial ProgressInitial topline data from the Phase II MaGic study is expected sooner than previously guided, indicating progress in the clinical trial timeline.
Financial PerformanceDianthus reported higher-than-expected license revenue and a smaller net loss than consensus estimates for 1Q25.
Pipeline DevelopmentThe ongoing Phase III CAPTIVATE study with DNTH103 in CIDP is expected to support a BLA filing, indicating progress in the company's pipeline.